Key result
A rare NR1D1::MAML1 epithelioid and spindle cell sarcoma initially mimicked pseudomyogenic hemangioendothelioma on core biopsy but was definitively diagnosed using next-generation sequencing.
Why the study?
Epithelioid and spindle cell sarcomas with NR1D1::MAML1/2 fusions are rare emerging entities that can mimic pseudomyogenic hemangioendothelioma, presenting a diagnostic pitfall.
Case Report (n=1)
Comprehensive molecular testing is essential to correctly identify rare NR1D1-rearranged sarcomas and avoid misdiagnosis as pseudomyogenic hemangioendothelioma.
Answers are grounded in this paper and cite their sources.
NR1D1::MAML1 fusion warrants consideration in hemangioendothelioma-like sarcomas to avoid misdiagnosis; leaves open systematic characterization of this rare entity.
Epithelioid and spindle cell sarcomas with NR1D1::MAML1/2 gene fusions are rare and emerging entities. Only six cases of NR1D1-rearranged mesenchymal tumors have previously been reported in the literature; they are often characterized by an epithelioid morphology, at least focal pseudogland formation, prominent cytoplasmic vacuoles, and focal to diffuse immunohistochemical expression of keratin. We herein report the first case of an NR1D1::MAML1 epithelioid and spindle cell sarcoma with dual immunohistochemical expression of ERG and FOSB, mimicking a pseudomyogenic hemangioendothelioma (PHE) on core biopsy. The sarcoma arose in the left forearm of a 64-year-old man. Initial biopsy showed a mesenchymal neoplasm composed of epithelioid and spindle cells dispersed in myxoid stroma with scattered stromal neutrophils. The morphologic features, combined with the dual immunohistochemical expression of ERG and FOSB, initially mimicked PHE, representing an important potential diagnostic pitfall. The patient subsequently underwent a radical resection, which showed a much more diffuse epithelioid appearance with nested architecture and pseudogland formation. Next-generation sequencing was performed on the resection specimen, which revealed an NR1D1::MAML1 gene fusion, confirming the final diagnosis. Given the fully malignant potential of this tumor, knowledge and recognition of this rare entity are essential to ensure proper management, prevent misdiagnosis, and further characterize the clinical course of this emerging entity. Comprehensive molecular testing can help to identify these rare tumors and exclude the possibility of epithelioid mimics, including PHE.
No takes yet. Share an insight, caveat, or question.
Warmke et al. (2023) conducted a case report in NR1D1::MAML1 epithelioid and spindle cell sarcoma (n=1). Next-generation sequencing and radical resection was evaluated. A rare NR1D1::MAML1 epithelioid and spindle cell sarcoma initially mimicked pseudomyogenic hemangioendothelioma on core biopsy but was definitively diagnosed using next-generation sequencing.
Synapse has enriched 10 related papers. Consider them for comparative context: